Literature DB >> 16448326

Novel therapeutic approaches to the treatment of Wilson's disease.

George J Brewer1.   

Abstract

The treatment of Wilson's disease has changed considerably in recent times, from the use of penicillamine (Cuprimine, Merck) for all stages and types of disease, to the use of three other anticopper drugs at appropriate times for appropriate patients. Each type and stage of the disease can be considered as a therapeutic target, for which specialised therapy is appropriate. This paper systematically reviews the various types and stages of Wilson's disease presentation, and provides opinion on the appropriate therapy for each. For patients presenting with neurological disease, the use of tetrathiomolybdate is optimum; for patients presenting with mild-to-moderate hepatic failure, a combination of trientine (Syprine, Merck) and zinc is recommended, whereas liver transplantation is necessary for those with severe failure; zinc therapy alone or trientine alone as second choice is recommended for patients presenting with hepatitis or cirrhosis without liver failure, for maintenance therapy, for treatment of presymptomatic patients and for treatment of paediatric and pregnant patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448326     DOI: 10.1517/14656566.7.3.317

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

2.  The Protective Role of Sulfated Polysaccharides from Green Seaweed Udotea flabellum in Cells Exposed to Oxidative Damage.

Authors:  Fernando Bastos Presa; Maxsuell Lucas Mendes Marques; Rony Lucas Silva Viana; Leonardo Thiago Duarte Barreto Nobre; Leandro Silva Costa; Hugo Alexandre Oliveira Rocha
Journal:  Mar Drugs       Date:  2018-04-20       Impact factor: 5.118

3.  Antioxidant Activity of Fucoidan Modified with Gallic Acid Using the Redox Method.

Authors:  Keylla Dayanne Coelho Marinho de Melo; Lucas Dos Santos Lisboa; Moacir Fernandes Queiroz; Weslley Souza Paiva; Ana Carolina Luchiari; Rafael Barros Gomes Camara; Leandro Silva Costa; Hugo Alexandre Oliveira Rocha
Journal:  Mar Drugs       Date:  2022-07-29       Impact factor: 6.085

4.  Advance in the pathogenesis and treatment of Wilson disease.

Authors:  Qin-Yun Dong; Zhi-Ying Wu
Journal:  Transl Neurodegener       Date:  2012-11-27       Impact factor: 8.014

5.  Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.

Authors:  San-Qing Xu; Xu-Fang Li; Hui-Yun Zhu; Yan Liu; Feng Fang; Ling Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

6.  Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China.

Authors:  Liang-Yong Li; Wen-Ming Yang; Huai-Zhen Chen; Yun-Hu Wu; Xiang Fang; Jing Zhang; Zhen Wang; Yong-Sheng Han; Yu Wang
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.